Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODSH in COPD Exacerbations
NCT00457951Phase 2Terminated
- Sponsor
- Chimerix Inc.
- Start
- Apr 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of dociparstat sodium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chimerix Inc. Primary endpoint: Incidence of Treatment Failure up to 31 days. Started Apr 2007; status: terminated.
02
Drugs
dociparstat sodium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00457951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457951.